New ultrasound technology developed at Johns Hopkins can distinguish fluid from solid breast masses with near perfect accuracy, an advance that could save patients, especially those with dense breast tissue, from unnecessary follow-up exams, painful procedures and anxiety.

Co-led by Rodrigo Toledo and Elena Garralda, IMMUNOMICS-VHIO is a platform for the discovery and validation of liquid biopsy biomarkers of immunotherapy outcomes.

Published today in Clinical Cancer Research, results from this project’s first study show that ultrasensitive circulating tumor DNA analysis can predict immunotherapy response in patients with advanced cancer across diverse tumor types and could potentially optimize patient management and therapeutic decision-making.

Scientists at St. Jude Children’s Research Hospital have shown in laboratory findings that a combination of drugs suppressing tumor cell development holds promise to treat the disease.

Researchers at the University of Houston are pushing the boundaries of biomedical innovation with a discovery that could transform treatment for cancer-induced cachexia, a debilitating syndrome characterized by the progressive loss of skeletal muscle mass. 

The team created a new tool that reduces bias and improves cancer diagnosis across populations

Bacteria may be the next frontier in cancer treatment, according to a team led by researchers at Penn State that devised a new approach of creating bacteria-derived mixtures — or cocktails — to help fight bladder cancer. They tested their mixtures of good and bad bacteria on patient tumor samples and in mice, finding that the cocktails significantly boost the immune system’s ability to fight cancer. 

Inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC) frequently overlap, forming a unique clinical entity termed PSC-IBD. A new review published in eGastroenterology highlights the complex bidirectional relationship between these conditions, particularly after colectomy and liver transplantation. While colectomy may not halt PSC progression, it influences cancer risk and pouch outcomes. Liver transplantation extends survival but alters IBD activity and malignancy risk. These findings highlight the need for longitudinal studies to guide surveillance, treatment, and surgical decisions.